Reimagining Medicine Q2 2023 Results slide image

Reimagining Medicine Q2 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Cardiovascular Immunology Ophthalmology Biosimilars Conclusions Neuroscience Global Health Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 87 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation